Skip Navigation

A Phase III Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA A02:01-Positive Participants With Previously Untreated Advanced Melanoma PRISM-MEL-301

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06112314

Study #:
STUDY00161344

Start Date:
May 28, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06112314

View Complete Trial Details & Eligibility at ClinicalTrials.gov